What is EpigenDx?
EpigenDx operates at the forefront of genomic and epigenomic research, specializing in the critical areas of disease biomarker discovery and molecular diagnosis. The company's core expertise lies in DNA methylation analysis, providing essential products and laboratory services to a diverse clientele including academic, government, and industrial researchers. Leveraging advanced techniques such as Pyrosequencing and bisulfite sequencing, EpigenDx is dedicated to advancing epigenomic research and delivering high-quality diagnostic solutions.
How much funding has EpigenDx raised?
EpigenDx has raised a total of $46K across 1 funding round:
Debt
$46K
Debt (2021): $46K with participation from PPP
Key Investors in EpigenDx
PPP
Public-Private Partnership
What's next for EpigenDx?
With significant Series B/C stage funding, EpigenDx is poised for substantial expansion. The recent capital injection is expected to fuel further development of its proprietary technologies and broaden its service offerings in the rapidly evolving field of precision medicine. This strategic investment will likely enable EpigenDx to scale its operations, enhance its research capabilities, and potentially forge new partnerships to accelerate the translation of genomic insights into clinical applications, solidifying its position as a key player in molecular diagnostics.
See full EpigenDx company page
